To understand whether active engagement of immune cells in vivo by trastuzumab can also mediate HER2 downregulation, we used a mouse xenograft tumor model that we showed immune cell engagement by trastuzumab previously [25]. The gene discussed is ERBB2; the disease is neoplasm.